Evaluation of investigator bias in industry-funded clinical trials of latanoprost

Canadian Journal of Ophthalmology

Volumn 46, Issue 6, 2011, Pages 531-536

  Jinapriya, Delan ^a,b   Anraku, Ayako ^a   Alasbali, Tariq ^a   Trope, Graham E ^a   Buys, Yvonne M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; LATANOPROST; TRAVOPROST;

ARTICLE; COHORT ANALYSIS; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84455180670     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2011.09.015     Document Type: Article

References (44)

1. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53supp l1:S93-105.
2. Rachmiel R, Trope GE, Chipman ML, et al. Effect of medical therapy on glaucoma filtration surgery rates in Ontario. Arch Ophthalmol. 2006;124:1472-7. (Pubitemid 44537149)
3. Alasbali T, Smith M, Geffen N, et al. Discrepancy between results and abstract conclusions in industry- vs nonindustry-funded studies comparing topical prostaglandins. Am J Ophthalmol. 2009;147:33-8.
4. Maul E, Carrasco FG, Costa VP, et al. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%. Clin Ther. 2007;29:1915-23. (Pubitemid 350212801)
5. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available at www.cochrane-handbook.org. Accessed March 19, 2011.
6. Kobayashi H, Kobayashi K, Okinami S. A comparison of intraocular pressure-lowering effect of prostaglandin F2-alpha analogues, latanoprost, and unoprostone isopropyl. J Glaucoma. 2001;10:487-592.
7. Tsukamoto H, Mishima HK, Kitazawa Y, et al. A comparative clinical study of latanoprost and isopropyl unoprostone in Japanese patients with primary open-angle glaucoma and ocular hypertension. J Glaucoma. 2002;11:497-501. (Pubitemid 36015108)
8. Kurtz S, Shemesh G. The efficacy and safety of once-daily versus onceweekly latanoprost treatment for increased intraocular pressure. J Ocul Pharmacol Ther. 2004;20:321-7. (Pubitemid 39108896)
9. Maruyama K, Shirato S, Haneda M. Evaluation of the additive effect of bunazosin on latanoprost in primary open-angle glaucoma. Jpn J Ophthalmol. 2005;49:61-2. (Pubitemid 40249005)
10. Koz OG, Ozsoy A, Yarangumeli A, et al. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial. Acta Ophthalmol Scand. 2007;85:838-43. (Pubitemid 350142805)
11. Ozdemir M, Ozdemir G. Comparison of the intraocular pressure lowering effect of latanoprost and carteolol-pilocarpine combination in newly diagnosed glaucoma. Jpn J Ophthalmol. 2003;47:72-6. (Pubitemid 36173874)
12. Diestelhorst M, Roters S, Krieglstein GK. The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients: a randomized, double-masked comparison with timolol 0.5%. Graefes Arch Clin Exp Ophthalmol. 1997;235:20-6.
13. Fristrom B, Nilsson SE. A double masked comparison of the intraocular pressure-reducing effect of latanoprost 0.005% and 0.001% administered once daily in open-angle glaucoma and ocular hypertension. Br J Ophthalmol. 1997;81:867-70. (Pubitemid 27469969)
14. Konstas AG, Maltezos AC, Gandi S, et al. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol. 1999;128:15-20. (Pubitemid 29315758)
15. O'Donoghue EP. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3-month, randomised study. Ireland Latanoprost Study Group. Br J Ophthalmol. 2000;84:579-82. (Pubitemid 30339305)
16. Orzalesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41:2566-73. (Pubitemid 30624384)
17. Aung T, Chew PT, Yip CC, et al. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2001;131:636-42. (Pubitemid 32422122)
18. DuBiner HB, Mroz M, Shapiro AM, Dirks MS, Brimonidine vs Latanoprost Study Group. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial. Clin Ther. 2001;23:1969-83. (Pubitemid 34073189)
19. Larsson LI. Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension. Ophthalmology. 2001;108:1439-44.
20. Susanna R Jr, Giampani J Jr, Borges AS, et al. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology. 2001;108:259-63. (Pubitemid 32115953)
21. Jampel HD, Bacharach J, Sheu WP, et al. Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure. Am J Ophthalmol. 2002;134:863-71. (Pubitemid 35425455)
22. Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology. 2003;110:609-14. (Pubitemid 36262750)
23. Konstas AG, Papapanos P, Tersis I, et al. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology. 2003;110:1357-60. (Pubitemid 36842471)
24. Dinslage S, Hueber A, Diestelhorst M, Krieglstein G. The influence of latanoprost 0.005% on aqueous humor flow and outflow facility in glaucoma patients: a double-masked placebo-controlled clinical study. Graefes Arch Clin Exp Ophthalmol. 2004;242:654-60. (Pubitemid 39242840)
25. Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol. 2004;138:389-95. (Pubitemid 39208565)
26. Susanna R Jr, Sheu WP. Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America. Clin Ther. 2004;26:755-68.
27. Susanna R Jr, Medeiros FA, Vessani RM, et al. Intraocular pressure fluctuations in response to the water-drinking provocative test in patients using latanoprost versus unoprostone. J Ocul Pharmacol Ther. 2004;20:401-10. (Pubitemid 39441780)
28. Walters TR, DuBiner HB, Carpenter SP, et al. Bimatoprost Circadian IOP Study Group. 24-hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol. 2004;49 suppl 1:S26-35. (Pubitemid 38324612)
29. Konstas AG, Katsimbris JM, Lallos N, et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology. 2005;112:262-6. (Pubitemid 40202562)
30. Magacho L, Reis R, Shetty RK, et al. Efficacy of latanoprost or fixedcombination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication. Ophthalmology. 2006;113:442-5.
31. Martinez A, Sanchez M. A comparison of the effects of 0.005% latanoprost and fixed combination dorzolamide/timolol on retrobulbar haemodynamics in previously untreated glaucoma patients. Curr Med Res Opin. 2006;22:67-73. (Pubitemid 43106909)
32. Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology. 2006;113:239-46. (Pubitemid 43170772)
33. Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006;47:2917-23. (Pubitemid 351639767)
34. Konstas AG, Kozobolis VP, Katsimpris IE, et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology. 2007;114:653-7. (Pubitemid 46483692)
35. Harasymowycz P, Hutnik CM, Nicolela M, Stewart WC. Latanoprost versus timolol gel-forming solution once daily in primary open-angle glaucoma or ocular hypertension. Can J Ophthalmol. 2007;42:75-81. (Pubitemid 46408898)
36. Konstas AG, Kozobolis VP, Tsironi S, et al. Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/ timolol fixed combination after 2 and 6 months of treatment. Ophthalmology. 2008;115:99-103.
37. Watson PG. Latanoprost: Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology. 1998;105:82-7. (Pubitemid 28070605)
38. Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol. 2000;84:710-3. (Pubitemid 30438546)
39. Kampik A, Arias-Puente A, O'Brart DP, Vuori ML, European Latanoprost Study Group. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study. J Glaucoma. 2002;11:90-6. (Pubitemid 34298588)
40. Inan UU, Ermis SS, Yucel A, Ozturk F. The effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial. Acta Ophthalmol Scand. 2003;81:155-60. (Pubitemid 36609217)
41. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688-703. (Pubitemid 36457976)
42. Narayanaswamy A, Neog A, Baskaran M, et al. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic latanoprost (Latoprost) in subjects with primary open-angle glaucoma or ocular hypertension. Indian J Ophthalmol. 2007;55:127-31.
43. Varma R, Hwang LJ, Grunden JW, Bean GW. Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials. Am J Ophthalmol. 2008;145:336-42.
44. Barden J, Derry S, McQuay HJ, Moore RA. Bias from industry trial funding? A framework, a suggested approach, and a negative result. Pain. 2006;121:207-18.